Price Chart

Profile

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
URL https://www.kuraoncology.com
Investor Relations URL https://ir.kuraoncology.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 07, 2024
Last Earnings Release Aug. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
URL https://www.kuraoncology.com
Investor Relations URL https://ir.kuraoncology.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Nov. 07, 2024
Last Earnings Release Aug. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A